GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Exenatide, Liraglutide

Company
University of Dundee
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01575301

    DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists

    Not yet reported University of Dundee 411 participants Est. completion 2015-12-11 4 sites
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02456428

    Incretin-based Drugs and the Risk of Heart Failure

    Canadian Network for Observational Drug Effect Studies, CNODES 1499650 participants Est. completion 2015-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02475499

    Incretin-based Drugs and Pancreatic Cancer

    Canadian Network for Observational Drug Effect Studies, CNODES 886172 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02476760

    Incretin-based Drugs and Acute Pancreatitis

    Canadian Network for Observational Drug Effect Studies, CNODES 1417914 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03151005

    The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

    Not yet reported Xinqiao Hospital of Chongqing 70 participants Est. completion 2021-04-23 1 site
    Other conditions: Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT03492580

    A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT04184947

    Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

    University of Padova 10000 participants Est. completion 2020-02-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05136287

    SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

    Jose Seijas Amigo 140 participants Est. completion 2024-01-01 11 sites
    Type 2 diabetes Other conditions: Weight Loss, Quality of Life, Safety Issues
    View official trial listing →
  • Status unknown NCT NCT05161429

    BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

    Brigham and Women's Hospital 550000 participants Est. completion 2024-06-30 5 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06449235

    Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site
    Other conditions: Type2diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07188545

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
    Metabolic syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.